1. Home
  2. BLMN vs ANL Comparison

BLMN vs ANL Comparison

Compare BLMN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bloomin' Brands Inc.

BLMN

Bloomin' Brands Inc.

HOLD

Current Price

$10.26

Market Cap

851.9M

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

BUY

Current Price

$10.58

Market Cap

998.8M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
BLMN
ANL
Founded
1988
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
851.9M
998.8M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
BLMN
ANL
Price
$10.26
$10.58
Analyst Decision
Hold
Strong Buy
Analyst Count
11
7
Target Price
$11.86
★ $29.50
AVG Volume (30 Days)
★ 2.4M
310.2K
Earning Date
11-06-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 106.71
N/A
EPS
★ 1.01
N/A
Revenue
★ $4,213,346,000.00
N/A
Revenue This Year
$0.65
$243.83
Revenue Next Year
$1.66
N/A
P/E Ratio
$9.96
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.19
$0.88
52 Week High
$12.63
$17.25

Technical Indicators

Market Signals
Indicator
BLMN
ANL
Relative Strength Index (RSI) 65.08 36.09
Support Level $7.74 $8.96
Resistance Level $11.75 $12.49
Average True Range (ATR) 0.46 1.45
MACD 0.22 -0.40
Stochastic Oscillator 88.63 5.63

Price Performance

Historical Comparison
BLMN
ANL

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: